The survival benefit of Usp18 heterozygous deletion was ablated when IFN signaling was disrupted (Supplementary Fig. 3f, g), confirming the link between USP18, IFN signaling, and anti-cancer phenotypes. The gene discussed is USP18; the disease is cancer.